TAmiRNA publishes new osteoporosis studies

Vienna, Austria: – Biotech innovators TAmiRNA has authored two new articles based on studies that investigate the role of microRNAs in osteoporosis.

Both articles can now be viewed online and increase the range of knowledge about the relationships between circulating MicroRNAs (miRNAa) and bone disease.

Bone microstructure

One study, published on the scientific online magazine www.nature.com, is based on the use of TAmiRNA’s osteomiR™ kit to identify bone-related circulating MicroRNAs (miRNAa) and their association to bone microstructure.

It suggests bone-related circulating miRNAs are significantly associated to dynamic processes of bone, reflected by bone histomorphometry.

WNT signaling

The other article, published in The Journal of Clinical Endocrinology and Metabolism, studies the altered MicroRNA Profile in osteoporosis caused by impaired WNT signalling.

The study team, including TAmiRNA founder and CEO Dr. Matthias Hackl, conclude that circulating miRNA patterns, reflecting WNT1 mutation status, provide novel insights into the mode of action of WNT1 osteoporosis.

MiRNA resources

These new studies significantly extend our understanding of the links between circulating MiRNAs and osteoporosis and bone disorders,” commented Dr. Hackl.

“They also illustrate the potency of our osteomiR™ kit and microRNA services in uncovering those links and connections,” he added.

About TAmiRNA

Privately owned and headquartered in Vienna, TAmiRNA GmbH is a biotech company specialized in the identification and validation of non-coding RNAs as biomarkers for age-related diseases. The mission of TAmiRNA is to provide clinically useful biomarkers to improve and prolong patient stability, health and quality of life with increasing age.

TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for early diagnosis and prognosis of disease, or as companion diagnostic tests to support treatment decisions.

TAmiRNA’s pipeline includes developments in osteoporosis, cardiovascular disease, type-2 diabetes, and cancer, which aim to provide ‘microRNA kit’ solutions that enable users to quantify the levels of specific microRNA combinations and platelet function in serum, plasma, urine or other biofluids. The company initially developed kits for bone disease (osteomiR) and cardiovascular and metabolic diseases (thrombomiR).

TAmiRNA also offers contract research services for companies in need of targeted biomarker development. Customers include biopharma companies with drug development programs in human and veterinary medicine, medtech companies and clinical research groups

More information available at: www.tamirna.com.